Abstract
Background/Aims
Methods
Results
Notes
FINANCIAL SUPPORT
The authors received no financial support for the research, authorship, and/or publication of this article.
AUTHOR CONTRIBUTION
Conceptualization: Alvarez-Bañuelos MT, Quezada-Gutiérrez C, Guzmán-García RE. Methodology: Alvarez-Bañuelos MT, Quezada-Gutiérrez C, Morales-Romero J. Validation: AlvarezBañuelos MT, Sampieri CL, Monte-Villaseñor E. Formal analysis: Morales-Romero J, Quezada-Gutiérrez C. Investigation: Quezada-Gutiérrez C, Alvarez-Bañuelos MT. Writing-original draft preparation: Quezada-Gutiérrez C, Alvarez-Bañuelos MT. Writing-review and editing: Sampieri CL, Morales-Romero J, Guzmán-García RE. Supervision: Alvarez-Bañuelos MT, Morales-Romero J, Monte-Villaseñor E. Approval of final manuscript: all authors.
ACKNOWLEDGMENTS
REFERENCES
Table 1.
Variable | No. of patients (%) |
---|---|
Age (yr) | |
< 65 | 208 (68.2) |
≥ 65 | 97 (31.8) |
Sex | |
Male | 178 (58.4) |
Female | 127 (41.6) |
Place of origin | |
Rural | 196 (64.3) |
Urban | 109 (35.7) |
Occupation | |
Worker | 163 (53.4) |
Housework | 116 (38.1) |
Unemployed | 26 (8.5) |
Clinical stagea | |
Local | 132 (51.2) |
Regional | 40 (15.5) |
Distant | 86 (33.3) |
Level of education | |
Illiterate | 132 (43.3) |
Primary/secondary education | 152 (49.8) |
High school/university | 21 (6.9) |
Location of the tumor | |
Blind | 40 (13.1) |
Ascending+descending colon | 81 (26.6) |
Transverse colon | 22 (7.2) |
Sigmoid | 52 (17.0) |
Straight | 110 (36.1) |
Tumor size (cm) | |
≤5 | 97 (34.8) |
> 5 | 182 (65.2) |
Metastatic lymph nodes | |
No | 250 (82.0) |
Yes | 55 (18.0) |
Location of metastasis | |
Liver | 41 (41.4) |
Lung | 15 (15.2) |
Bone | 5 (5.0) |
Others | 38 (38.4) |
Table 2.
Variable |
Education |
P-valuea | |
---|---|---|---|
Low (n=284) | High (n=21) | ||
Age (yr) | 0.070 | ||
< 65 | 190 (66.9) | 18 (87.5) | |
≥ 65 | 94 (33.1) | 3 (14.3) | |
Sex | 0.170 | ||
Male | 167 (58.8) | 11 (52.4) | |
Female | 117 (41.2) | 10 (47.6) | |
Place of origin | 0.002 | ||
Rural | 189 (66.5) | 7 (33.3) | |
Urban | 95 (33.5) | 14 (66.7) | |
Occupation | 0.730 | ||
Worker | 151 (49.5) | 12 (57.1) | |
Unemployed | 55 (50.5) | 9 (42.9) | |
Clinical stage | 0.960 | ||
Early | 87 (30.6) | 6 (28.6) | |
Advanced | 153 (53.9) | 12 (57.5) | |
Unclassified | 44 (15.5) | 3 (14.3) | |
Location of the tumor | 0.230 | ||
Blind | 38 (13.5) | 2 (9.5) | |
Ascending+descending colon | 77 (27.3) | 4 (19.0) | |
Transverse colon | 17 (7.4) | 4 (19.0) | |
Sigmoid | 47 (16.7) | 4 (19.0) | |
Straight | 103 (36.5) | 7 (33.3) | |
Tumor size (cm) | 0.190 | ||
2–5 | 93 (35.8) | 4 (21.1) | |
> 5 | 167 (64.2) | 15 (78.9) | |
Metastatic lymph nodes | < 0.001 | ||
No | 239 (84.2) | 11 (52.4) | |
Yes | 45 (15.8) | 10 (47.6) | |
Location of metastasis | 0.030 | ||
Liver | 40 (41.7) | 1 (33.3) | |
Lung | 13 (13.5) | 2 (66.7) | |
Others | 43 (44.8) | 0 | |
Type of treatment (n = 261) | 0.170 | ||
Surgery | 18 (18.2) | 1 (5.0) | |
Chemotherapy | 23 (23.2) | 5 (25.0) | |
Radiotherapy | 1 (1.0) | 1 (5.0) | |
Surgery and chemotherapy | 37 (37.4) | 10 (50.0) | |
Surgery and radiotherapy | 3 (3.0) | 1 (5.0) | |
Chemotherapy and radiotherapy | 7 (7.1) | 1 (5.0) | |
Surgery+chemotherapy+radiotherapy | 10 (10.1) | 1 (5.0) | |
Type of chemotherapy (n = 182) | 0.590 | ||
Neoadjuvant | 61 (33.5) | 5 (27.8) | |
Adjuvant | 121 (66.5) | 13 (72.2) | |
Scheme of chemotherapy (n = 163) | 0.960 | ||
Oxaliplatin | 59 (39.6) | 5 (35.7) | |
XELOX | 37 (24.8) | 4 (28.6) | |
FOLFOX | 15 (10.1) | 2 (14.3) | |
5 FU | 20 (13.4) | 16 (14.3) | |
Others | 18 (12.1) | 1 (7.1) |
Table 3.
Variable | No. of subjects | 2-Year survival rate (%)a | 5-Year survival rate (%)a | P-valueb |
---|---|---|---|---|
Age (yr) | 0.03 | |||
< 65 | 208 | 68 | 48 | |
≥ 65 | 97 | 56 | 28 | |
Sex | 0.62 | |||
Male | 178 | 67 | 44 | |
Female | 127 | 61 | 38 | |
With partner or spouse | 0.89 | |||
Yes | 111 | 65 | 45 | |
Do not | 194 | 63 | 33 | |
Provenance zone | 0.85 | |||
Urban | 109 | 65 | 43 | |
Rural | 196 | 63 | 39 | |
Level of education | 0.02 | |||
Low | 284 | 62 | 37 | |
High | 21 | 86 | 86c | |
Employment situation | 0.34 | |||
Worker | 163 | 70 | 42 | |
Unemployed | 142 | 58 | 36 | |
Socioeconomic level | NAd | |||
Low | 295 | 63 | 38 | |
High | 10 | 99.9 | 99.9 |
Table 4.
Variable | No. | 2-Year survival rate (%)a | 5-Year survival rate (%)a | P-valueb |
---|---|---|---|---|
Clinical stage | < 0.001 | |||
Early | 93 | 82 | 68 | |
Advanced | 165 | 56 | 22 | |
Tumor location | 0.700 | |||
Descendent colon | 21 | 75 | 75 | |
Blind | 40 | 75 | 55c | |
Transverse colon | 21 | 63 | 50d | |
Rectum | 110 | 61 | 46 | |
Ascendant colon | 60 | 60 | 33 | |
Sigmoid colon | 51 | 84 | 19 | |
Tumor size (cm) | 0.700 | |||
< 2 | 11 | 60 | 45e | |
2–5 | 86 | 66 | 49 | |
> 5 | 182 | 65 | 39 | |
Metastatic lymph node | 0.110 | |||
0 | 249 | 60 | 42 | |
1–3 | 29 | 68 | 34f | |
≥ 4 | 26 | 88 | 0 | |
Presence metastasis | < 0.001 | |||
Negative | 204 | 71 | 57 | |
Positive | 101 | 47 | 0 | |
Distant metastases | 0.008 | |||
Lung | 15 | 74 | 48g | |
Liver | 41 | 24 | 0h | |
Lung and liver | 9 | 0 | 0 | |
Bone | 5 | 53 | 0 | |
Others | 29 | 57 | 0 | |
Histologic grade | 0.170 | |||
Grade 1 | 195 | 24 | 41 | |
Grade 2 | 68 | 70 | 39 | |
Grade 3 | 32 | 50 | 37i | |
Type of chemotherapy | 0.150 | |||
Adjuvant | 61 | 61 | 34 | |
Neoadjuvant | 121 | 70 | 40 | |
Scheme of chemotherapy | 0.320 | |||
5 FU | 22 | 73 | 63 | |
Capecitabine | 16 | 57 | 57 | |
Oxaliplatin | 64 | 70 | 43 | |
FOLFOX | 17 | 62 | 31 | |
XELOX | 41 | 68 | 0 | |
Others | 3 | 50 | 0 |